490 results about "Use medication" patented technology

The invention relates to application of a combined pharmaceutical composition in preparation of a medicine for resisting transforming follicular lymphoma. Active components in the combined pharmaceutical composition comprise a first component and a second component, the first component is selected from any one or a combination of at least two of sitagliflozin, pharmaceutically acceptable salt, isomer, solvate and metabolite of sitagliflozin; and the second component is selected from any one or a combination of at least two of chidamide, pharmaceutically acceptable salts, isomers, solvates and metabolites of the chidamide. Research finds that the combined use of the two active components not only can reduce the dosage of each drug and improve the medication safety, but also has the effect of improving or treating convertible follicular lymphoma more remarkably than that of a single drug active component, and plays a role in synergistic promotion. The invention provides an effective drug combination strategy for improvement or treatment of convertible follicular lymphoma, and has very significant significance.

The invention discloses a drug-combined anticancer composition and application of the composition in preparation of anticancer drugs. According to the present invention, the drug combination composition comprises the PARP inhibitor Olaparib and the calcium ion antagonist amlodipine maleate, the PARP inhibitor Olaparib and the calcium ion antagonist amlodipine maleate provide the synergistic effect, and compared with the single PARP inhibitor, the drug combination composition has characteristics of high stomach cancer sensitivity, significant gastric cancer efficiency improving, and wide application prospect. The Amlodipine in the drug combination composition provided by the invention enhances the curative effect of the PARP inhibitor Olaparib on the gastric cancer.

The present invention provides a pharmaceutical composition, the composition comprises a therapeutically effective amount of bumetanib, one or more specific antioxidants and other necessary one or more pharmaceutically acceptable pharmaceutic adjuvants, and the specific antioxidants are selected from one or more of fat-soluble vitamin C derivatives or phenolic antioxidants. In addition, the invention also discloses a method for improving the stability of the bumetanib pharmaceutical composition. According to the technical scheme, the problems of generation and growth of N-nitroso bumetanib and other related substances in the production and storage process of the bumetanib solid preparation are effectively solved, and the drug stability and the medication safety are remarkably improved.

The invention discloses an icaritin carbamate prodrug as well as a preparation method and application thereof, belongs to the field of pharmacy, and particularly relates to an icaritin carbamate prodrug as shown in a formula 3-N or 7-N and pharmaceutically acceptable salts thereof as well as a preparation method and application of the icaritin carbamate prodrug. Specifically, a main metabolic site (3-site or 7-site hydroxyl) of a natural flavone compound icaritin is subjected to structural modification through a chemical synthesis method, and an appropriate group is introduced into the site to form the icaritin carbamate prodrug. Amines adopted by the carbamate are aliphatic amines. Due to existence of a carbamate structure, II-phase metabolism of icaritin in SD rats is reduced, compared with icaritin raw material medicine, the 3-N-01 prodrug has the advantages that oral bioavailability is remarkably improved, the 3-N-01 prodrug is the optimal prodrug, clinical medication is expected to be capable of reducing administration dosage and improving patient compliance, and the 3-N-01 prodrug can be applied to preparation of the SD rats. And an effective strategy is expected to be provided for improving the oral bioavailability of phenolic drugs. # imgabs0 #

A drug combination of purinostat mesylate and an analog thereof for preventing and treating multiple myeloma, and the use thereof. Specifically, provided is a three-drug or four-drug combination of purinostat mesylate and an analog thereof, dexamethasone and other drug, which drug combination has significantly enhanced synergistic anti-tumor activity in vitro and in vivo, synergistically inhibits the expression of the key survival protein in multiple myeloma, is superior to existing clinical combination regimens, and has no significant toxic side effects. In addition, the drug combination significantly down-regulates the expression of CDK6, and overcomes the drug resistance to an immunomodulator. In particular, the three-drug combination of puisostat mesylate, a glucocorticoid and an immunomodulator has an excellent prevention and treatment effect on multiple myeloma, especially relapsed / refractory multiple myeloma.

The invention relates to the technical field of pharmaceutical preparations, in particular to a docetaxel oral self-microemulsion composition and a preparation process thereof. The docetaxel oral self-microemulsion composition is prepared from docetaxel, an oil phase, a surfactant, a cosurfactant, a stabilizer and an antioxidant, the oil phase is caprylic / capric acid mono / diglyceride, medium chain triglyceride, caprylic acid propylene glycol ester or lauric acid propylene glycol ester. The docetaxel oral self-microemulsion composition provided by the invention has relatively high drug loading capacity, good physical and chemical stability and relatively high bioavailability, and is more suitable for clinical medication.

The invention discloses a ferroptosis inhibitor and application of the ferroptosis inhibitor in radiation pneumonitis drugs, and relates to the technical field of biological medicines. The specific preparation method comprises the following steps: adding the ferroptosis inhibitor and the auxiliary agent into the solvent, and dissolving to obtain the ferroptosis inhibitor composition; wherein the ferroptosis inhibitor is isoorientin; the auxiliary agent is a glucosamine derivative; the solvent is a serum-free DMEM culture medium. The ferroptosis inhibitor composition prepared by the method provided by the invention can effectively reduce the rise of active oxygen, ferrous ions and malondialdehyde levels of human pulmonary epithelial cells BEAS-2b and mouse pulmonary epithelial cells MLE-12 caused by irradiation, restore cell mitochondrial membrane potential enrichment and inhibit the expression of various inflammatory factors in irradiated cells; therefore, the process of radiation pneumonitis is remarkably improved, and a new medication strategy is provided for research on radiation pneumonitis drugs.

Disclosed in the present invention is a compound represented by formula (I), or a pharmaceutically acceptable salt, ester or solvate thereof. Such a PSMA compound has higher tumor uptake and / or lower or substantially equivalent kidney uptake, can improve the drug targeting effect and / or reduce the kidney injury risk, and is conducive to better meeting the medication needs of patients.

The invention provides application of combined use of baicalin and magnesium ions in preparation of nasal cavity medicines for treating cerebral apoplexy. The invention also provides a pharmaceutical composition for treating cerebral apoplexy. The bioavailability of baicalin and magnesium ions in the brain is improved. Magnesium ions can block calcium ions and inhibit glutamic acid excitatory toxicity in the stroke incidence process, and baicalin has multiple biological activities such as inflammation resistance, oxidation resistance and neuroprotection. Experiments prove that the combined application of magnesium ions and baicalin prolongs the survival time, neurological scoring, weight recovery and behavioral improvement of cerebral apoplexy model mice; when the two medicines are combined for use, after respective dosages are halved, the treatment effect on cerebral apoplexy is stronger than that of a single medicine.

The invention provides an inhalation medication auxiliary device, relates to the technical field of medical instruments, and solves the technical problem that a large force is needed when a puncture part of an inhaler is pressed to puncture a capsule. The inhalation medication auxiliary device comprises a shell and an automatic puncturing module, and the shell covers an inhaler and is used for fixing the inhaler; the automatic puncturing module is arranged on the shell and used for automatically puncturing the capsule placed in the inhaler. According to the embodiment of the invention, the automatic puncturing of the capsule in the inhaler is realized through the automatic puncturing module arranged on the shell, so that the technical problems that large force is needed when the puncturing part of the inhaler is pressed to puncture the capsule, a user with weak force is difficult to press, and the inhaler is not friendly to old and young users are solved.

Provided are a sustained-release microsphere for polypeptide drugs, a pharmaceutical formulation thereof, a method for preparing same, and use thereof. The method comprises the following steps: forming an inner aqueous phase; forming an oil phase; forming an outer aqueous phase; and dispersing the inner aqueous phase into the oil phase to give a primary emulsion, then re-dispersing the primary emulsion into the outer aqueous phase to give a pre-secondary emulsion, emulsifying the pre- secondary emulsion to form a secondary emulsion, and finally curing the secondary emulsion to give the sustained-release microsphere. The method features ease to operate, and the obtained sustained-release microsphere possesses ideal drug release behaviors (low early burst release, and stable mid- and later-stage releases) and safety and potency in reducing blood glucose, and is thus suitable for stable, long-term use with good patient compliance.

The invention belongs to the technical field of biological medicines, and particularly relates to application of quercetin combined with curcumin in preparation of an anti-allergic reaction medicine. Through a large number of researches, the inventor finds that combined administration of quercetin and curcumin with a specific concentration can effectively inhibit mast cell degranulation, and the inhibition rate of mast cell degranulation reaches 90% or more, so that I-type anaphylaxis mediated by immune globulin E is inhibited, especially systemic anaphylaxis, and the curative effect is good. The compound can be used for preparing anti-anaphylaxis drugs. The drug combination scheme provided by the invention has important significance and wide application prospect in drugs for treating or preventing anaphylactic reactions.

The present application relates to a pharmaceutical combination of a PARP7 inhibitor combined medication, and a use thereof in treating tumors. The pharmaceutical combination comprises: a first active ingredient PARP7 inhibitor, a second active ingredient CTLA-4 inhibitor or platinum complex, and optionally a third active ingredient PD-1 inhibitor or PD-L1 inhibitor.

The invention provides the aprepitant and palonosetron hydrochloride compound emulsion for injection, the compound emulsion has better stability, nausea and vomiting can be more conveniently and effectively prevented and treated, and the medication compliance of patients is improved.

Provided are a ginsenoside F1 nasal mucosa formulation and a preparation method therefor and use thereof. The ginsenoside F1 nasal mucosa formulation is prepared using ginsenoside F1 as an active ingredient, together with a nasal mucosa absorption promoter and water, and optionally contains borneol and a bacteriostatic agent. The ranges of the mass percentage of the components are preferably as follows: 0.4-15% of ginsenoside F1, 0-0.8% of borneol, 0.05-40% of the absorption promoter, and 0-0.3% of the bacteriostatic agent. The nasal formulation can be used for treating senile dementia and can improve and restore memory. The nasal solution has the following advantages: improving the solubility of the ginsenoside F1 in water and thereby significantly improving the bioavailability of systemic absorption of ginsenoside F1, and enabling increase in the concentration of ginsenoside F1 in the intracerebral focus by means of formula adjustment according to therapeutic requirements and thereby significantly improving the therapeutic effect for diseases and the safety of drug use.

The invention relates to a nintedanib dry powder inhalant as well as a preparation method and application thereof. The dry powder inhalant comprises nintedanib and magnesium stearate. According to the nintedanib dry powder inhalant, by controlling the adding proportion of magnesium stearate and the particle size distribution of co-micro powder, the dosage of fine particles can be remarkably increased, the nintedanib dry powder inhalant still has the high dosage of fine particles under the high drug loading capacity, the drug bioavailability is high, and the safety risk of a patient in the medication period can be reduced. Meanwhile, the preparation method of the nintedanib dry powder inhalant is simple and controllable, and the final product is safe, reliable and high in stability.

The invention discloses a production and preparation method of palatability-enhanced compound double-flower oral liquid, and relates to the technical field of traditional Chinese medicine preparations. The production and preparation method of the oral liquid comprises the following steps: pretreatment of medicinal materials: taking herba andrographitis, honeysuckle, radix isatidis, fructus forsythiae, honey and dark plum, washing, denucleating and slicing the dark plum (the honey is in a liquid state and does not need to be pretreated), ultrasonic extraction, integrated purification, filtrate collection, dynamic taste modification, sterilization and filling; the method has the advantages that bitter components are accurately neutralized by an innovative gradient inclusion process, qualitative leap of a bitter masking effect is realized, sensory evaluation is verified according to international standards, children acceptance score reaches an excellent level (full score of 10 scores), the core problem that children refer to take medicines due to bitter taste is thoroughly solved, the treatment compliance of patients is remarkably improved, and the treatment cost is reduced. The continuity of medication is ensured, a breakthrough solution is provided for the field of medication for children, and meanwhile, a technical normal form is provided for improvement of medicines similar to bitter taste.

The invention provides a loxoprofen sodium double-release capsule micro-tablet and a preparation method of the loxoprofen sodium double-release capsule micro-tablet. Through the synergistic effect of the quick-release micro-tablet and the sustained-release micro-tablet, the quick-release micro-tablet can realize quick release and absorption, and the sustained-release micro-tablet can maintain relatively stable blood concentration for a long time. The administration frequency is reduced, the coordination of the postprandial administration requirement and the dietary habit is ensured, and the occurrence of gastrointestinal tract adverse reactions is reduced. The preparation provided by the invention conforms to the dosage form design of the hour pharmacology, can quickly take effect through administration twice every day, can maintain the blood concentration in the high-incidence time period of night diseases, avoids the disadvantage of taking medicine after meal when the night diseases attack, guarantees the sleep quality, and improves the overall treatment effect. The micro tablet is small in size and easy to swallow, and the medication compliance of patients with dysphagia is obviously improved. Through dosage form design and improvement, unmet clinical requirements are expected to be met by virtue of obvious advantages of the traditional Chinese medicine composition.

The invention provides a briracetam sustained-release pharmaceutical composition as well as a preparation method and application thereof. The pharmaceutical composition comprises a pharmaceutical active ingredient and a pharmaceutical excipient, wherein the pharmaceutical excipient is selected from one or more of a framework material, a disintegrating agent, a swelling agent, an adhesive, a filler and a lubricant. The briracetam sustained-release pharmaceutical composition disclosed by the invention is good in sustained-release effect, stable in release speed and small in side effect, the medicine taking frequency is reduced, and the compliance of a patient is improved; the retention time of the medicine in the stomach is prolonged, so that the medicine is continuously released in the stomach and is absorbed at the upper end of the small intestine, the effect of continuously taking effect for 24 hours is achieved, the plasma concentration is stable, and the adverse reaction is small; a patient is prevented from randomly interrupting medication, and disease relapse and malignant complication development are prevented; the medicine is few in administration times, convenient to take and small in toxic and side effects.

The present invention discloses an N-acetylcysteine xylitol injection and its preparation method, which comprises raw materials with the following mass-volume ratios: 0.020 - 0.035 g / mL of N-acetylcysteine, 0.015 - 0.030 g / mL of xylitol, 0.005 - 0.010 g / mL of pH regulator, and the balance being injection water. The method of the present invention can reduce the oxidation and degradation of N-acetylcysteine during the preparation of the medicinal solution by controlling the dissolution concentration, temperature and range of the residual headspace oxygen amount of N-acetylcysteine, and selecting a pH regulator with an appropriate concentration to control the pH value of the medicinal solution and controlling the preparation time, thereby improving the stability of the product quality and controlling the generation of related substances. The present invention significantly improves the quality stability of the N-acetylcysteine xylitol injection, ensures the safety of patients' medication, and makes the product have broad application prospects and value.

The utility model relates to the technical field of airflow detection, in particular to an inspiration airflow detection device, which comprises an airflow channel which is a longitudinal ventilation cavity enclosed by a shell. The airflow guide cavity is formed in the top of the airflow channel, a first ventilation opening is formed in the bottom end of the shell, and a second ventilation opening is formed in the side wall of the airflow guide cavity; the second air vent is used for being communicated with an air inlet of the dry powder medicine preparation, and the shape of the second air vent is matched with that of the air inlet of the dry powder medicine preparation connected with the second air vent; and the sensor mechanism is arranged on the side wall of the shell. The inspiration airflow detection device provided by the utility model can be matched with a dry powder medicine preparation for use, is used for detecting the flow rate of the inspiration airflow of a patient in the medication process, and solves the problem that a gas flow sensor is difficult to be matched with the dry powder medicine preparation in the prior art.

The invention relates to the field of pharmaceutical preparations, and discloses a compound preparation composition containing olopatadine and brimonidine for a nasal cavity and a preparation method of the compound preparation composition. The compound preparation composition for the nasal cavity is prepared from the following components in percentage by weight: 0.01 to 0.5 percent of olopatadine and 0.01 to 0.5 percent of brimonidine. According to the compound preparation composition, olopatadine and brimonidine are combined for use, the curative effect is remarkably improved compared with single-drug treatment, a good synergistic interaction effect is shown, multiple pharmacological effects are achieved through one-time drug administration, and drug use convenience and long-term treatment compliance are greatly improved.

The invention provides an application of combination of indobufen and butylphthalide in preparation of a drug for preventing and / or treating cerebrovascular diseases, indobufen and butylphthalide are combined for use, have a synergistic effect, remarkably improve the treatment effect, can be used for preparing the drug for preventing, secondarily preventing or treating the cerebrovascular diseases, and has a wide application prospect. The medicine is especially suitable for treating cerebral apoplexy and transient ischemic attack, and can be used for prophylactically improving cerebral infarction caused by cerebral arterial thrombosis.

The invention discloses application of licochalcone as a drug sensitizer and an anti-tumor drug composition. The application comprises an application of the acanthochalcone in preparation of an anti-tumor drug sensitizer and an application of the acanthochalcone in improvement of the anti-tumor efficacy of platinum chemotherapeutic drugs, and the invention further provides an anti-tumor composition capable of efficiently inhibiting platinum drug-resistant gastric cancer cells based on the application. Through a gastric cancer organ model and an in-vitro cytology experiment, it is found that the acanthochalcone has an inhibiting effect on proliferation of gastric cancer cells, and the sensitivity of the gastric cancer cells to platinum drugs can be remarkably enhanced. The invention also finds that IC50 of gastric cancer cells to cis-platinum and oxaliplatin, especially platinum acquired drug-resistant gastric cancer cells, can be significantly reduced by combined use of the acanthochalcone and platinum drugs. Therefore, the invention provides a new medication basis and choice for overcoming acquired platinum drug resistance of gastric cancer by utilizing the acanthochalcone.

The invention belongs to the field of pharmaceutical preparations. The invention relates to a novel dosage form of an isavuconazole sulfate freeze-dried tablet, and a prescription and a process for preparing the isavuconazole sulfate freeze-dried tablet by adopting a freeze-drying method. The isavuconazole sulfate freeze-dried tablet is prepared from isavuconazole sulfate serving as a main drug and pharmaceutic adjuvants. Water is not needed during taking, and the tablet can be rapidly disintegrated after being put in the mouth and is suitable for patients with dysphagia such as old people and children; the production process of the isavuconazole sulfate freeze-dried orally disintegrating tablet is simple in technology, easy to control and suitable for industrial production.

The invention discloses application of tangeretin in preparation of a medicine for treating hearing loss. The invention proposes and verifies that the tangeretin can effectively protect the spiral ganglion neurons for the first time, and avoids the death of the cells caused by cisplatin medication; experimental data show that the preventive tangeretin drug can effectively prevent hearing loss of adult mice and greatly relieve sensorineural deafness caused by cis-platinum, and a new thought is provided for clinical ototoxicity drug administration.

The invention provides a viscose dispersing type transdermal patch of a VMAT2 (Vitamin Matrix Activator 2) inhibitor 11-P4S. The transdermal patch is composed of a backing layer, a drug-containing substrate layer and an anti-sticking layer, wherein the drug-containing layer comprises 11-P4S free alkali and pharmaceutically acceptable salts thereof, a polyacrylate pressure-sensitive adhesive, a crystallization inhibitor, a transdermal absorption enhancer and an antioxidant. The viscose dispersing type transdermal patch can continuously release drugs within 24 hours, is stable in drug release, high in bioavailability and good in safety, can greatly improve the medication compliance and medication convenience of a patient with delayed dyskinesia (TD) on the basis of ensuring the clinical curative effect, reduces the nursing burden of nursing personnel, and is suitable for treating TD diseases.

Provided are a preparation method for and the use of an icaritin carbamate prodrug and a salt thereof, which belong to the pharmaceutical field. In particular, provided are an icaritin carbamate prodrug represented by formula 3-N or 7-N and a pharmaceutically acceptable salt thereof, and a preparation method therefor and the use thereof. Specifically, the icaritin carbamate prodrug is formed by subjecting a main metabolic site (3-site or 7-site hydroxyl) of a natural flavonoid compound icaritin to structural modification by means of a chemical synthesis method, and introducing a suitable group at the position. Amines used in such carbamates are aliphatic amines. The presence of the carbamate structure reduces the phase II metabolism of icaritin in SD rats. Compared with an icaritin bulk drug, the 3-N-01 prodrug has a significantly improved oral bioavailability, making same the optimal prodrug. In clinical medication, the prodrug is expected to be able to reduce the administration dosage and improve patient compliance, and is expected to offer an effective strategy for improving the oral bioavailability of phenolic drugs.

The invention discloses a traditional Chinese medicine compound composition with an effect of preventing and treating radioactive injury as well as a preparation method and application thereof. The traditional Chinese medicine compound composition is prepared from 5-15 parts of American ginseng, 3-6 parts of sea-buckthorn and 10-30 parts of rhizoma polygonati. The composition is proportioned and optimized according to the theory of treatment based on syndrome differentiation, and the medicines are combined to achieve the effects of tonifying qi, activating blood and nourishing yin. Clinical experiment results show that the traditional Chinese medicine compound composition provided by the invention has a remarkable effect of preventing and treating radioactive injury, particularly has a remarkable curative effect in the aspects of improving oral mucositis, dry mouth, weakness, sleep disorder and the like after radiotherapy, and is safe in clinical medication.

The invention discloses application of carboxamidotriazole combined chemotherapeutic drugs in preparation of drugs for treating solid tumors, which mainly aims at the chemotherapeutic drugs such as gemcitabine, docetaxel or albumin paclitaxel to achieve the technical effects of effect enhancement and toxicity reduction, and the solid tumors are lung cancer, breast cancer, liver cancer and kidney cancer. In-vivo and in-vitro researches prove that the combination of carboxamidotriazole and gemcitabine, docetaxel or albumin paclitaxel can achieve a remarkable combined synergistic effect, and does not increase toxic and side effects, so that the carboxamidotriazole can benefit more patients through clinical combined medication.